Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer

Simple item page
dc.contributor.authorLisy, K.
dc.date.issued2013
dc.description.abstractObjective: To assess whether histamine type 2 receptor antagonists (H2RAs) improve overall survival when used as pre-, peri-, or postoperative therapy in patients with colorectal cancer who had surgical resection with curative intent.
dc.description.statementofresponsibilityKarolina Lisy
dc.identifier.citationClinical Journal of Oncology Nursing, 2013; 17(2):211-212
dc.identifier.doi10.1188/13.CJON.211-212
dc.identifier.issn1092-1095
dc.identifier.issn1538-067X
dc.identifier.orcidLisy, K. [0000-0003-2604-4290]
dc.identifier.urihttp://hdl.handle.net/2440/84892
dc.language.isoen
dc.publisherOncology Nursing Society
dc.rights© Oncology Nursing Society.
dc.source.urihttps://doi.org/10.1188/13.cjon.211-212
dc.subjectHumans
dc.subjectColorectal Neoplasms
dc.subjectHistamine H2 Antagonists
dc.subjectCombined Modality Therapy
dc.subjectChemotherapy, Adjuvant
dc.titleHistamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications